Skip to content
OpenCapital
Get started

Ironwood Pharmaceuticals IRWD EV / EBITDA

EV / EBITDA at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
12×+3.9×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
525.2×—
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
4.3×-1.7×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
8.1×-16.2×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
7.4×-1.4×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
16.4×-5.2×

Other financials

Income statement

See full
Revenue$106.5M+159%
Operating income$72.6M+349%
Net income$40.8M+209%
EPS (diluted)$0.24+204%

Balance sheet

See full
Cash & equivalents$220.5M+103%
Total debt$212.4M+1,323%
Total equity-$217.1M+35.0%
Total assets$434.6M+32.8%

Cash flow

See full
Operating cash flow$5.1M-74.3%
CapEx-—
Free cash flow$74.6M+390%

Valuation

See full
Market cap$632.12M+457%
Enterprise value$624M+3,024%
P/E6.2×—
P/S1.8×+1.4×

Profitability

See full
Gross margin99.2%—
Operating margin55.4%+38.7pp
Net margin28.3%+22.3pp
FCF margin24.7%-11.1pp

Returns & leverage

See full
Return on equity29.7%-138pp
Debt / equity0×-0.5×
Current ratio1.4×-1.9×

Where this comes from

Calculated from Ironwood Pharmaceuticals’s reported figures.

enterprise value/ebitda=2.8×

Based on the most recent quarter.

The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ironwood Pharmaceuticals's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ironwood Pharmaceuticals's EV / EBITDA?
Ironwood Pharmaceuticals (IRWD) reported EV / EBITDA of 2.8× in Q1 2026.
How has Ironwood Pharmaceuticals's EV / EBITDA changed year-over-year?
Ironwood Pharmaceuticals's EV / EBITDA increased by 7.2% year-over-year, from 2.6× to 2.8×.
What is the long-term trend for Ironwood Pharmaceuticals's EV / EBITDA?
Over 4 years (2020 to 2025), Ironwood Pharmaceuticals's EV / EBITDA has grown at a -14.6% compound annual growth rate (CAGR), from 10.2× to 5.4×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.